The COVID-19 pandemic triggered an unprecedented surge in clinical research, leading to thousands of studies aimed at understanding, managing, and ultimately controlling the virus. As healthcare systems worldwide faced the immense challenge of treating patients, researchers raced against time to … Read More
covid 19
ACTIV-6 Trial: Inhaled Fluticasone in Covid-19
The ACTIV-6 trial, published in the New England Journal of Medicine in 2023, examines the effectiveness of inhaled fluticasone furoate in the treatment of non-hospitalized patients with mild to moderate COVID-19. The trial was a decentralized, double-blind, randomized, placebo-controlled study … Read More
ACTT-2 Trial Summary: Baricitinib + Remdesivir in Covid-19
2020 ACTT-2 TRIAL Baricitinib plus Remdesivir for Hospitalized Adults with Covid-1 Double-blind, randomized, placebo-controlled trial M Objective: To compare the clinical efficacy of combination of baricitinib plus remdesivir with remdesivir alone among hospitalized adults with laboratory-confirmed Covid-19. 1033 patients Patients … Read More
ACTT-1 Trial Summary: Remdesivir in Covid-19
2020 ACTT-1 TRIAL Remdesivir for the Treatment of Covid-19 Double-blind, randomized, placebo-controlled trial Objective: To evaluate the clinical efficacy and safety of putative investigational therapeutic agent remdesivir among hospitalized adults with laboratory-confirmed Covid-19. M Patients with lab-confirmed SARS-CoV-2 infection 1,063 … Read More
ACTT-4 Trial Summary: Baricitinib in Covid-19
2022 ACTT-4 TRIAL Baricitinib versus dexamethasone for adults hospitalised with COVID-19 double-blind, double placebo-controlled, randomised controlled trial M Objective: To compare baricitinib in combination with remdesivir versus dexamethasone with remdesivir at preventing progression to mechanical ventilation or death 1010 patients … Read More
ACTIV-4B Trial Summary: Antithrombotic Therapy in Covid-19
2021 ACTIV-4B TRIAL Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19 minimal-contact, adaptive, randomized, double-blind, placebo-controlled Objective: To assess whether anticoagulant or antiplatelet therapy can safely reduce major adverse cardiopulmonary outcomes among symptomatic but … Read More
ACTIV-3 Trial: Monoclonal Antibody for Covid-19
2020 ACTIV-3 TRIAL Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 Multicenter, open-label, randomized comparative trial M Objective: To assess the efficacy of LY-CoV555, a neutralizing monoclonal antibody in hospitalized Covid-19 patients without end-organ damage. Hospitalized patients with Covid-19 who … Read More
ACTION Trial Summary: Anticoagulation for Hospitalized Covid-19 Patients
2021 ACTION TRIAL: Therapeutic vs. prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer Pragmatic, open-label (with blinded adjudication), multicentre, randomised Objective: to evaluate therapeutic anticoagulation compared with prophylactic anticoagulation among patients admitted with coronavirus disease 2019 … Read More
MICHELLE Trial Summary: Rivaroxaban for Thromboprophylaxis in Covid-19
2022 MICHELLE TRIAL Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 Pragmatic, open-label, multicentre, randomized controlled trial Objective: To investigate if extended thromboprophylaxis with Rivaroxaban after hospitalization due to COVID-19 decrease rates of venous & arterial thromboembolism … Read More